Boehringer Ingelheim registers Phase 1 bioequivalence trial for vicadrostat/empagliflozin
The trial will compare two tablet formulations of vicadrostat combined with empagliflozin in healthy volunteers.
Boehringer Ingelheim registered a new Phase 1 pharmacokinetics trial this week.
- The trial, titled "Bioequivalence of Two Different Vicadrostat / Empagliflozin Formulations Following Oral Administration in Healthy Trial Participants," is designed to establish the bioequivalence of two different formulations of vicadrostat / empagliflozin in healthy male and female trial participants following oral administration.1 The study is listed as not yet recruiting, with an estimated start date of 2026-10-14 and an estimated enrollment of 36 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.